Obesity Clinical Trial
Official title:
Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Obesity: a Randomized, Double-blind Controlled Trial
The purpose of this study is to determine whether the probiotics will be effective in the treatment of obesity
| Status | Recruiting |
| Enrollment | 100 |
| Est. completion date | December 2017 |
| Est. primary completion date | December 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 15 Years to 60 Years |
| Eligibility |
Inclusion Criteria: 1. Age 15-60 years 2. BMI=28.0kg/m2 3. Agree to cooperate in the trial 4. Provision of written informed consent Exclusion Criteria: 1. With chronic gastrointestinal diseases, severe immune deficiency, lactose intolerance 2. Diabetes 3. Use antibiotics, bacteriostatic agents (eg berberine), lipid-lowering drugs, antacids, H2 Blockers, proton pump inhibitors, corticosteroids or sex hormones 4. Use any probiotics in the last 3 months 5. Allergic constitution 6. Participating in any other clinical trials 7. Was not able to insist until the end 8. Pregnant and lactating women |
| Country | Name | City | State |
|---|---|---|---|
| China | Shanghai 10th People's Hospital | Shanghai | Shanghai |
| Lead Sponsor | Collaborator |
|---|---|
| Shanghai 10th People's Hospital |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | change from baseline in fasting blood-glucose at 1 month | change of the fasting blood-glucose will be calculated at 1 month in comparison with the baseline | 1 month | |
| Primary | change from baseline in fasting blood-glucose at 3 months | change of the fasting blood-glucose will be calculated at 3 months in comparison with the baseline | 3 months | |
| Primary | change from baseline in glycosylated hemoglobin change at 1 month | change of the glycosylated hemoglobin will be calculated at 1 month in comparison with the baseline | 1 month | |
| Primary | change from baseline in glycosylated hemoglobin change at 3 months | change of the glycosylated hemoglobin will be calculated at 3 months in comparison with the baseline | 3 months | |
| Secondary | change from baseline in gut microbiota at 1 month | study the microbiota change of stool samples at 1 month in comparison with the baseline | 1 month | |
| Secondary | change from baseline in gut microbiota at 3 months | study the microbiota change of stool samples at 3 months in comparison with the baseline | 3 months | |
| Secondary | change from baseline in triglyceride at 1 month | 1 month | ||
| Secondary | change from baseline in triglyceride at 3 months | 3 months | ||
| Secondary | change from baseline in cholesterol at 1 month | 1 month | ||
| Secondary | change from baseline in cholesterol at 3 months | 3 months | ||
| Secondary | change from baseline in high-density lipoprotein at 1 month | 1 month | ||
| Secondary | change from baseline in high-density lipoprotein at 3 months | 3 months | ||
| Secondary | change from baseline in low-density lipoprotein at 1 month | 1 month | ||
| Secondary | change from baseline in low-density lipoprotein at 3 months | 3 months | ||
| Secondary | change from baseline in glutamic oxalacetic transaminase at 1 month | 1 month | ||
| Secondary | change from baseline in glutamic oxalacetic transaminase at 3 months | 3 months | ||
| Secondary | change from baseline in alkaline transaminase at 1 month | 1 month | ||
| Secondary | change from baseline in alkaline transaminase at 3 months | 3 months | ||
| Secondary | change from baseline in alkaline phosphatase at 1 month | 1 month | ||
| Secondary | change from baseline in alkaline phosphatase at 3 months | 3 months | ||
| Secondary | change from baseline in superoxide dismutase at 1 month | 1 month | ||
| Secondary | change from baseline in superoxide dismutase at 3 months | 3 months | ||
| Secondary | change from baseline in C-reactive protein at 1 month | 1 month | ||
| Secondary | change from baseline in C-reactive protein at 3 months | 3 months | ||
| Secondary | change from baseline in uric acid at 1 month | 1 month | ||
| Secondary | change from baseline in uric acid at 3 months | 3 months | ||
| Secondary | change from baseline in tumor necrosis factor-a at 1 month | 1 month | ||
| Secondary | change from baseline in tumor necrosis factor-a at 3 months | 3 months | ||
| Secondary | change from baseline in interleukin-6 at 1 month | 1 month | ||
| Secondary | change from baseline in interleukin-6 at 3 months | 3 months | ||
| Secondary | change from baseline in interleukin-8 at 1 month | 1 month | ||
| Secondary | change from baseline in interleukin-8 at 3 months | 3 months | ||
| Secondary | change from baseline in fasting insulin at 1 month | 1 month | ||
| Secondary | change from baseline in fasting insulin at 3 months | 3 months | ||
| Secondary | change from baseline in c peptide at 1 month | 1 month | ||
| Secondary | change from baseline in c peptide at 3 months | 3 months | ||
| Secondary | change from baseline in visceral fat fraction at 1 month | 1 month | ||
| Secondary | change from baseline in visceral fat fraction at 3 months | 3 months | ||
| Secondary | change from baseline in body age at 1 month | 1 month | ||
| Secondary | change from baseline in body age at 3 months | 3 months | ||
| Secondary | change from baseline in percentage of body fat at 1 month | 1 month | ||
| Secondary | change from baseline in percentage of body fat at 3 months | 3 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |